Hostname: page-component-7b7567c8c-z4zkx Total loading time: 0 Render date: 2026-11-17T17:29:40.561Z Has data issue: false hasContentIssue false

Pneumococcal Infections and Pneumococcal Vaccine: An Update

Published online by Cambridge University Press:  02 January 2015

Michael W. Rytel*
Affiliation:
Division of Infectious Diseases, Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin
*
Milwaukee County Medical Complex, 8700 West Wisconsin Avenue, Milwaukee, WI 53226

Abstract

Pneumococcal pneumonia continues to be an important disease in terms of prevalence, morbidity and mortality. With the discovery of penicillin and its wide clinical use, the overall mortality of pneumococcal pneumonia has been significantly reduced, but problems remain. These include: 1) death rate is uninfluenced by the antibiotic in the first five days of illness; 2) death rate in certain high risk groups and in patients infectecd with type 3 pneumococcus exceeds 25%; and 3) penicillin resistant strains of pneumococci have emerged. Because of these and other considerations, a modern 14-valent pneumococcal vaccine has been developed by Robert Austrian and his co-workers. The vaccine has been found to be immunogenic and effective in a number of populations studied. Additional efficacy studies are needed, however, particularly in certain high risk groups, such as the elderly and immunocompromised patients.

Information

Type
Original Articles
Copyright
Copyright © The Society for Healthcare Epidemiology of America 1982

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable